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Reducing early preterm birth for 25c a day 
Invited Editorial 
Preterm birth (before 37 weeks of gestation) is the most common direct cause of 
death and disability in children (1). Early preterm birth (EPTB) (less than 34 weeks) 
is the main cause of neonatal death and severe disability (2). Most women who 
experience early preterm birth are low risk (1). In those women who have already 
experienced one early preterm birth, we can involve tertiary hospital clinics and 
implement strategies such as cervical screening and either vaginal progesterone 
therapy or cervical suturing (3). However, these measures require levels of clinical 
expertise that are not available at a global level. Even within Australia, some rural 
women do not have access to trained ultrasonographers who can perform reliable 
transvaginal scanning necessary to detect cervical shortening. In many countries in 
the world, any sort of ultrasound scan in pregnancy is not feasible, let alone access 
to secondary interventions following on from discovery of a short cervix such 
progesterone therapy or cervical suturing. Tertiary hospital clinics are simply a 
dream.   
The severe consequences of early preterm birth and high cost and need for 
clinical expertise in existing strategies of prevention, has lead to calls for a public 
health approach to reduce the rate of early preterm birth (3). Implementation of 
omega 3 long chain polyunsaturated fatty acids (omega-3 LCPUFA) supplements in 
pregnancy is now a feasible and cost effective public health strategy (4,5,6). 
The omega 3 LCPUFA story is remarkable and involves multidisciplinary 
researchers from around the world. The discovery is a gold standard in progressing 
from benchtop to bedside in medical research.  The journey started with basic 
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science studies evaluating the mechanisms of initiation of labour, progressed 
through observational and epidemiological studies of populations, advanced into 
randomised trials testing a specific hypothesis and culminated in a Cochrane 
Review.   
Understanding the omega-3 LCPUFA story begins with knowledge of factors 
leading to the initiation of cervical ripening and labour (3, 7-11). Omega-3 LCPUFA 
enter the materno-feto-placental unit from the maternal circulation. Tissue 
concentrations are heavily influenced by diet (3,7,9). Increases in omega-3 LCPUFA 
levels in cervical tissues directly counter local production of pro-inflammatory 2-
series prostaglandins such as PGE2 and PGF2 within those same tissues, resulting 
in a delicate balance in hormonal drivers that inhibit cervical ripening and those that 
augment these processes. The balance plays a critical role in the duration of 
gestation (9). Omega-3 LCPUFA are a direct dietary antagonist of the production of 
2-series prostaglandins in the cervix. Arachidonic acid directly competes with 
omega-3 LCPUFA for incorporation into cells. Diets that are high in omega-3 
LCPUFA result in preferential incorporation of the 3-series prostaglandins into 
cellular phospholipids and the displacement of arachidonic acid and this results in 
lower outputs of 2-series prostaglandins (3,10). If endogenous levels of 2-series 
prostaglandins within the cervix are too high, or local availability of omega-3 
LCPUFA to act as an antagonist are too low, the cervix may prematurely ripen, basal 
uterine contractions increase in strength, and the outcome may be preterm birth 
(7,8,9,10,11).  
 A population strategy to reduce preterm birth would therefore need to target 
either: 
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a) reducing endogenous levels of pro-inflammatory series 2 prostaglandins such as 
PGE2 and PGF2 in the cervix and the underlying disease processes that lead to 
these; or 
b) increase materno-feto-placental levels of omega-3 LCPUFA through diet or 
supplementation.   
 Research into the human microbiome and specifically the role of the materno-
feto-placental microbiome on altering endogenous concentrations of pro-
inflammatory 2-series prostaglandins as measured using new molecular 
technologies is an emerging field of research for the former intervention (12,13). 
However the development of drugs and obstetric management based upon 
microbiome and pro-inflammatory markers is still at least a decade from fruition. In 
contrast, increasing materno-feto-placental tissue levels of omega-3 LCPUFA could 
be easily implemented through dietary modification or supplementation.   
The next step in the scientific journey was to investigate whether dietary 
deficiency of omega-3 LCPUFA was a clinical concern and whether there was any 
association between diet and preterm birth. This heralded the need for observational 
and epidemiological studies. Observational studies consistently documented that 
many pregnant women did indeed have a diet low in omega-3 LCPUFA 
(10,14,15,16). In Australia, there was evidence that diets were poor and most 
pregnant women did not consume sufficient omega-3 LCPUFA. Despite a long 
standing global recommendation for an intake of 300 mg/d of omega-3 LCPUFA per 
day in pregnancy, most Australian and American women consumed less than a third 
of the recommended daily intake (17).   
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Epidemiological studies also found a consistent association between 
populations with poor dietary intake of omega-3LCPUFA and preterm birth 
(14,15,16). One interesting early epidemiological study evaluated the rates of 
preterm birth in the Faro Island and Denmark. These closely linked geographical and 
genetic populations differed only in dietary fish intake and rates of preterm birth and 
provided an excellent case study to support the hypothesis (15).  
The observational and epidemiological studies were an important step in 
developing the hypothesis to be tested in randomised trials that a dietary supplement 
might reduce preterm birth. They also helped identify the type of supplement that 
would work best. The largest early study was the Australian DOMInO Trial 
(Docosahexaenoic acid (DHA) to Optimise Mother Infant Outcomes)(4). In a pre-
planned analysis, it was reported that omega-3 LCPUFA supplementation halved the 
rate of early preterm birth (RR 0.49; 95% CI 0.25-0.94) and the need for admission 
to a neonatal intensive care unit (RR 0.57, 95% CI 0.34-0.97, p=0.04)(4). 
A second key outcome of the DOMInO study was the safety evaluation. There 
was no increase risk of hospitalisation, caesarean section, pre-eclampsia or other 
serious morbidity. Of note side effects that might be attributable to omega-3 LCPUFA 
such as maternal nose bleeds, vaginal blood loss, constipation, nausea or vomiting 
were also not elevated in supplemented women (4).  However, there was an 
increased risk of post dates pregnancy and therefore the ORIP study was designed 
to address whether ceasing supplementation at term might be beneficial (17).      
Following publication of DOMInO, there was a call for more randomised trials 
to establish the generalisability of findings. These trials have now been performed 
and an updated Cochrane review involving 19,787 women reported a 42% reduction 
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in early preterm birth and 11% reduction in preterm birth with the implementation of 
prenatal supplementation with omega-3 LCPUDFA (6). The Cochrane team advise 
that no new trials to evaluate the benefits in singleton pregnancy should be 
performed (6). They outlined that further research into the impact in multiple 
pregnancy and on supplement timing remain outstanding questions.   
Omega-3 LCPUFA are not a drug. They are not covered by a patent. They 
can be manufactured easily in accredited health food supplement factories. Mass 
production brings the retail cost of tablets to 20 cents a day. The Cochrane review 
concluded the minimum effective dose is 500mg of DHA each day from week 12 of 
pregnancy (6). A widespread public health message should now try and implement 
this advice. 
It is important the message provided to pregnant women is clear. They need 
to buy the right omega-3 LCPUFA in the right dose and take it from 12 weeks of 
pregnancy.  We need to recommend brands with validated manufacturing controls to 
avoid unscrupulous traders. One way to help ensure pregnant women do take the 
correct dose, type and purity of supplement may be to consider implementation of a 
PBS subsidized prescription for a 24 week supply of 500mg of DHA taken once 
daily. This would help ensure our most vulnerable pregnant women can access the 
right intervention. An alternative would be to create a mechanism by which health 
care professionals and pregnant women could ensure a supplement met obstetric 
requirements and was manufactured in an accredited facility. 
Obstetric care providers have be very supportive of previous public health 
nutritional supplementation strategies such as use of folic acid to prevent neural tube 
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defects. The cost benefit ratio of omega-3 LCPUFA supplementation is even greater, 
and widespread adoption into clinical practice should now occur. 
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